Related Experiment Video
Updated: Apr 19, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
MYC gene rearrangements detected by interphase fluorescence in situ hybridization in diffuse large B-cell lymphomas
J A Misharina1, V V Sitko2, S V Klymenko2
1National Medical University O.O. Bohomolets, boulevard T.Shevchenko, 13, Kiev, 01601, Ukraine.
Insights
Interphase fluorescence in situ hybridization (I-FISH) accurately identifies MYC and IGH gene translocations in diffuse large B-cell lymphoma (DLBCL). This molecular-cytogenetic analysis aids in lymphoma diagnosis, prognosis, and treatment, particularly for refractory cases.
Area of Science:
- Hematology
- Oncology
- Cytogenetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most prevalent B-cell non-Hodgkin lymphoma (B-NHL).
- Chromosomal translocations, particularly MYC gene dysregulation, are key genetic aberrations in B-cell lymphomas, including Burkitt's lymphoma.
- Accurate diagnosis and prognostication are crucial for effective DLBCL management.
Purpose of the Study:
- To enhance the diagnostic accuracy of DLBCL.
- To identify specific chromosomal abnormalities, including MYC gene translocations (t(8;14)(q24;q32)), in lymphoma cells.
- To evaluate the utility of tri-color interphase fluorescence in situ hybridization (I-FISH) for detecting these abnormalities.
Main Methods:
- Lymph node biopsy specimens from 17 DLBCL and 3 Burkitt's lymphoma patients were analyzed.
- Paraffin-embedded tissues were subjected to I-FISH analysis using a commercial Vysis IGH/MYC, CEP 8 tri-color probe.
- The study focused on identifying rearrangements of the MYC gene and immunoglobulin heavy chain (IGH) gene.
Main Results:
- MYC and IGH gene translocations were detected in 4 out of 20 patients.
- The I-FISH method successfully identified MYC and IGH gene rearrangements in paraffin-embedded lymphoma tissue.
- Molecular-cytogenetic abnormalities were found in 8 out of 20 B-cell lymphoma patients.
Conclusions:
- I-FISH is an effective method for identifying MYC and IGH gene rearrangements in lymphoma tissues.
- Detecting these molecular-cytogenetic abnormalities aids in verifying DLBCL diagnosis.
- This approach can improve clinical course prediction and therapeutic strategies, especially for refractory lymphoma cases.
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma, including approximately 30-40% of all B-cell non-Hodgkin lymphomas (B-NHL). Chromosomal translocations are the hallmark of genetic aberrations in B-lymphoma and are often associated with a specific subtype of B-NHL. MYC gene dysregulation due to chromosomal translocations is characteristic for the most cases of Burkitt's lymphoma. Objective. The goal of this study was to improve the diagnostic accuracy of DLBCL. Identification of chromosome 8 and 14 abnormalities including the translocation of MYC gene t(8; 14)(q24; q32) in substrate cells of lymph nodes was applied using the method of tri-color interphase fluorescence in situ hybridization (I-FISH). Materials and methods. Lymph node biopsy specimens of 17 patients with diffuse large B-cell lymphoma and three patients with Burkitt's lymphoma (including one participant of liquidation of consequences of the catastrophe at the Chornobyl NPP) were studied. The age of patients ranged from 10 to 66 years old (41.3 ± 3.7 average). Biopsy specimens fixed in paraffin. I-FISH-analysis was performed using the commercial test Vysis IGH/MYC, CEP 8 tri-color, dual fusion translocation probe (Abbott Molecular, USA). Results and conclusions. MYC gene and immunoglobulin heavy chain (IGH) gene translocations were found in four out of twenty persons. Consequently the I-FISH method allows identification of of MYC and IGH gene rearrangements in tissue cells substrate of lymphoma fixed in paraffin. Using this method the molecular-cytogenetic abnormalities were found in eight of twenty patients with B-cell lymphoma providing verification of the lymphoma diagnosis, prediction of their clinical course and advance in management i.e increase the effectiveness of therapy, in refractory lymphoma cases among others.

